McFarlane Toys, a subsidiary of Todd McFarlane Productions, Inc., is a company started by Todd McFarlane that makes highly detailed models of characters from movies, comics, popular music, video games and sporting genres. McFarlane has attracted both acclaim and criticism for offering a select range of action figurines that graphically depict torture, mutilation, bondage and murder. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Kislov R.,University of Manchester | Waterman H.,Mcfarlane | Harvey G.,University of Adelaide | Boaden R.,University of Manchester
Implementation Science | Year: 2014

Background: Knowledge mobilisation in healthcare organisations is often carried out through relatively short-term projects dependent on limited funding, which raises concerns about the long-term sustainability of implementation and improvement. It is becoming increasingly recognised that the translation of research evidence into practice has to be supported by developing the internal capacity of healthcare organisations to engage with and apply research. This process can be supported by external knowledge mobilisation initiatives represented, for instance, by professional associations, collaborative research partnerships and implementation networks. This conceptual paper uses empirical and theoretical literature on organisational learning and dynamic capabilities to enhance our understanding of intentional capacity building for knowledge mobilisation in healthcare organisations. Discussion: The discussion is structured around the following three themes: (1) defining and classifying capacity building for knowledge mobilisation; (2) mechanisms of capability development in organisational context; and (3) individual, group and organisational levels of capability development. Capacity building is presented as a practice-based process of developing multiple skills, or capabilities, belonging to different knowledge domains and levels of complexity. It requires an integration of acquisitive learning, through which healthcare organisations acquire knowledge and skills from knowledge mobilisation experts, and experience-based learning, through which healthcare organisations adapt, absorb and modify their knowledge and capabilities through repeated practice. Although the starting point for capability development may be individual-, team- or organisation-centred, facilitation of the transitions between individual, group and organisational levels of learning within healthcare organisations will be needed. Summary: Any initiative designed to build capacity for knowledge mobilisation should consider the subsequent trajectory of newly developed knowledge and skills within the recipient healthcare organisations. The analysis leads to four principles underpinning a practice-based approach to developing multilevel knowledge mobilisation capabilities: (1) moving from 'building' capacity from scratch towards 'developing' capacity of healthcare organisations; (2) moving from passive involvement in formal education and training towards active, continuous participation in knowledge mobilisation practices; (3) moving from lower-order, project-specific capabilities towards higher-order, generic capabilities allowing healthcare organisations to adapt to change, absorb new knowledge and innovate; and (4) moving from single-level to multilevel capability development involving transitions between individual, group and organisational learning.


Calman L.,University of Manchester | Beaver K.,University of Central Lancashire | Hind D.,University of Sheffield | Lorigan P.,Christie NHS Foundation Trust | And 2 more authors.
Journal of Thoracic Oncology | Year: 2011

Introduction: The burden of lung cancer is high for patients and carers. Care after treatment may have the potential to impact on this. We reviewed the published literature on follow-up strategies intended to improve survival and quality of life. Methods: We systematically reviewed studies comparing follow-up regimes in lung cancer. Primary outcomes were overall survival (comparing more intensive versus less intensive follow-up) and survival comparing symptomatic with asymptomatic recurrence. Quality of life was identified as a secondary outcome measure. Hazard ratios (HRs) and 95% confidence intervals from eligible studies were synthesized. Results: Nine studies that examined the role of more intensive follow-up for patients with lung cancer were included (eight observational studies and one randomized controlled trial). The studies of curative resection included patients with non-small cell lung cancer Stages I to III disease, and studies of palliative treatment follow-up included limited and extensive stage patients with small cell lung cancer. A total of 1669 patients were included in the studies. Follow-up programs were heterogeneous and multifaceted. A nonsignificant trend for intensive follow-up to improve survival was identified, for the curative intent treatment subgroup (HR: 0.83; 95% confidence interval: 0.66-1.05). Asymptomatic recurrence was associated with increased survival, which was statistically significant HR: 0.61 (0.50-0.74) (p < 0.01); quality of life was only assessed in one study. Conclusions: This meta-analysis must be interpreted with caution due to the potential for bias in the included studies: observed benefit may be due to systematic differences in outcomes rather than intervention effects. Some benefit was noted from intensive follow-up strategies. More robust data, in the form of randomized controlled trials, are needed to confirm these findings as the review is based primarily on observational studies. Future research should also include patient-centered outcomes to investigate the impact of follow-up regimes on living with lung cancer and psychosocial well-being. Copyright © 2011 by the International Association for the Study of Lung Cancer.


Farquhar M.C.,Mcfarlane | Prevost A.T.,King's College London | Mccrone P.,King's College London | Brafman-Price B.,University of Cambridge | And 4 more authors.
BMC Medicine | Year: 2014

Background: Breathlessness is common in advanced cancer. The Breathlessness Intervention Service (BIS) is a multi-disciplinary complex intervention theoretically underpinned by a palliative care approach, utilising evidence-based non-pharmacological and pharmacological interventions to support patients with advanced disease. We sought to establish whether BIS was more effective, and cost-effective, for patients with advanced cancer and their carers than standard care. Methods: A single-centre Phase III fast-track single-blind mixed-method randomised controlled trial (RCT) of BIS versus standard care was conducted. Participants were randomised to one of two groups (randomly permuted blocks). A total of 67 patients referred to BIS were randomised (intervention arm n = 35; control arm n = 32 received BIS after a two-week wait); 54 completed to the key outcome measurement. The primary outcome measure was a 0 to 10 numerical rating scale for patient distress due to breathlessness at two-weeks. Secondary outcomes were evaluated using the Chronic Respiratory Questionnaire, Hospital Anxiety and Depression Scale, Client Services Receipt Inventory, EQ-5D and topic-guided interviews. Results: BIS reduced patient distress due to breathlessness (primary outcome: -1.29; 95% CI -2.57 to -0.005; P = 0.049) significantly more than the control group; 94% of respondents reported a positive impact (51/53). BIS reduced fear and worry, and increased confidence in managing breathlessness. Patients and carers consistently identified specific and repeatable aspects of the BIS model and interventions that helped. How interventions were delivered was important. BIS legitimised breathlessness and increased knowledge whilst making patients and carers feel 'not alone'. BIS had a 66% likelihood of better outcomes in terms of reduced distress due to breathlessness at lower health/social care costs than standard care (81% with informal care costs included). Conclusions: BIS appears to be more effective and cost-effective in advanced cancer than standard care. Trial registration: RCT registration at ClinicalTrials.gov NCT00678405 (May 2008) and Current Controlled Trials ISRCTN04119516 (December 2008).


Lapner P.L.C.,Ottawa Hospital Research Institute | Wood K.S.,University of Ottawa | Zhang T.,Ottawa Hospital Research Institute | Athwal G.S.,Mcfarlane
Journal of Shoulder and Elbow Surgery | Year: 2015

Background: During shoulder arthroplasty, the subscapularis tendon is released and repaired. Whether subscapularis strength subsequently returns to normal is poorly understood. This study's purpose was to determine whether subscapularis strength returns to normal after shoulder replacement and whether any preoperative factors predict the return of strength postoperatively. Methods: Sixty-four patients underwent unilateral shoulder arthroplasty. Subscapularis strength was compared between the surgical and contralateral (normal) limbs at baseline (preoperatively) and follow-up. In addition, operative arm subscapularis strength recovery was compared with ipsilateral supraspinatus strength recovery. Independent variables were assessed for their effect on subscapularis strength, including sex, age, dominant-side surgery, preoperative strength, preoperative external rotation, subscapularis management technique, and fatty infiltration. Results: The mean subscapularis strength ratio at 24months from baseline was 1.19±2.23 (. P=.0007). The normal side was significantly stronger than the operative side at all time points (. P<.0001). The operative-side subscapularis mean strength ratio was 0.54±0.28 of normal at baseline and 0.70±0.24 at 24months. Defining normal strength as ±15%, 15% of patients were normal at baseline up to 22% at 24months. At 24months, the mean supraspinatus strength ratio from baseline (3.13±6.11) was significantly greater than the subscapularis mean strength ratio (. P=.0007). Multivariable regression analysis did not demonstrate any correlation (. P>.05) between the independent variables studied and final subscapularis strength. Discussion: Although significant strength improvement from baseline was observed at 2years after shoulder arthroplasty, subscapularis strength returned to normal in only a minority of patients. Potential prognostic variables associated with final subscapularis strength remain elusive. © 2015 Journal of Shoulder and Elbow Surgery Board of Trustees.


Lapner M.,University of Alberta | Willing R.,Binghamton University State University of New York | Johnson J.A.,St Josephs Health Center | Johnson J.A.,University of Western Ontario | King G.J.W.,Mcfarlane
Clinical Biomechanics | Year: 2014

Background Hemiarthroplasty is a treatment option for selected distal humerus fractures. The purpose of this study was to determine the effect of distal humeral hemiarthroplasty and implant size on elbow articular contact. We hypothesized that implants of varying sizes produce different contact patterns compared with the native elbow. Methods Eight cadaveric arms were tested in an elbow simulator and the kinematics recorded. Three-dimensional reconstructions of bones and cartilage were generated from computed-tomography images to determine contact patterns. The native articulation was compared to optimal, oversized, and undersized implants (Latitude Anatomic Hemiarthroplasty). Changes in contact patterns relative to the native articulation were measured using total contact area and contact patch agreement scores, defined as the sum of distance between contact patches × area, indicating how well contact patches agree with the native contact pattern. Findings The native articulation had significantly lower ulnohumeral contact patch agreement scores compared to all tested implants (P < 0.05). Mean ulnohumeral and radiocapitellar contact area decreased an average 44% (P = 0.03) and 4% (P = 0.07) following placement of an optimally sized implant. There was no effect of implant size on contact area or contact patch agreement score (P > 0.05). Interpretation Shape differences of elbow implants relative to the native joint may be responsible for altered contact patterns and could be improved with design modifications. These changes may predispose the elbow to arthritis. The lack of influence of implant size suggests that implant shape and materials may be more important than implant sizing during surgery. © 2014 Elsevier Ltd. All rights reserved.


Patent
Mcfarlane | Date: 2012-12-14

A method for the treatment of seborrhoea in a patient comprises administering to the patient an effective amount of (24RS) or (24S) scymnol, an ester thereof or a pharmaceutically acceptable salt of a said ester, or of (24R) scymnol.


Patent
Mcfarlane | Date: 2013-02-18

The present invention is a garment having a limited number of insulation panels combined therewith which cover a high percentage of the surface area of the garment. In other words, the present invention uses relatively large insulation panels to cover a large area of the garment for maximum efficiency and insulation to the user. The insulation panels comprise an aerogel material.


Patent
Mcfarlane | Date: 2014-03-17

A multi-task single-pass agricultural tillage implement is disclosed. The implement has a plurality of independently engageable and adjustable soil working components successively mounted on a mainframe. The mainframe has a wheel assembly which raises and lowers a plurality of wheels. The mainframe also includes a tongue assembly coupleable to a towing vehicle and a frame pivoting angle adjustment mechanism. Each of the soil working components can be independently and selectively operated separately or in combination with any one or more of the plurality of working components such that each of the plurality of soil working components is independently, selectively operated for optimized single pass tillage. An open spiral chopping reel assembly for use in an agricultural field preparation implement is also disclosed


King G.J.,Mcfarlane
Instructional course lectures | Year: 2015

For more than 60 years, total elbow arthroplasty (TEA) has been successfully used to treat a variety of elbow conditions. Although first designed to treat older patients with rheumatoid arthritis, the indications have expanded to include younger, higher-demand patients with a broad range of elbow pathology. Two groups of TEA currently exist. The first group includes linked or semiconstrained elbows with a mechanical connection between the humeral and ulnar components that prevents disassociation. These implants do not rely on muscular or ligamentous tissues for stability. The second group includes unlinked implants that have no physical connection between the humeral and ulnar components. They rely on bearing surface architecture as well as soft-tissue integrity for elbow stability. Critical to the success of unlinked implants is a thorough preoperative evaluation of elbow stability, including bone stock, collateral ligament integrity, and periarticular muscle function. Unlinked implants should apply less strain to the bone-cement-implant interfaces, which may theoretically decrease rates of bearing wear and aseptic loosening. For this reason, some surgeons prefer unlinked implants for younger, higher-demand patients. To date, unlinked implants have not been clinically shown to improve survivorship compared with linked devices. No prospective randomized trials comparing linked and unlinked TEAs are currently available. Historically, unlinked implants have had higher revision rates, mostly caused by instability and early design flaws. More recent series have shown no significant differences in outcomes compared with linked devices. Unlinked TEA provides reliable pain relief and improved range of motion for patients with a variety of elbow disorders. Diligent patient selection and careful surgical technique are of utmost importance when considering an unlinked TEA as a treatment option. The recent development of convertible implants now allows surgeons to make intraoperative decisions regarding elbow stability and convert to a linked implant without revising the stems.


Trademark
Mcfarlane | Date: 2011-11-21

Cosmetics; skincare preparations, skin creams, skin lotions; hair lotions; essential oils. Pharmaceutical preparations; medicated, therapeutic or topical ointments, creams and lotions.

Loading Mcfarlane collaborators
Loading Mcfarlane collaborators